髋部骨折后假体周围骨折的发病率、危险因素与预后:揭示抗骨质疏松药物的保护作用
该回顾性队列研究利用台湾全民健康保险研究数据库分析48,082例髋部骨折患者,发现443例(0.9%)发生假体周围骨折,2285例(4.8%)发生对侧第二次髋部骨折。髋部骨折后启用抗骨质疏松药物与假体周围骨折风险降低相关(HR 0.50;95%CI 0.39-0.65),也与对侧第二次髋部骨折风险降低相关(HR 0.85;95%CI 0.77-0.93)。
要点
- 髋部骨折后启用抗骨质疏松药物与假体周围骨折风险降低相关(HR 0.50;95%CI 0.39-0.65)。
- 髋部骨折后启用抗骨质疏松药物与对侧第二次髋部骨折风险降低相关(HR 0.85;95%CI 0.77-0.93)。
- 假体周围骨折组5年死亡率与对侧第二次髋部骨折组相当(33.0% vs 30.0%),但严重骨质疏松性骨折更常见(7.5% vs 3.7%)。
核心结论
- 假体周围骨折是髋部骨折后的严重并发症。
- 髋部骨折后启用抗骨质疏松药物似乎可降低假体周围骨折和对侧第二次髋部骨折的风险,支持其作为关键预防策略的作用。
- 需要进一步研究以优化治疗方案。
研究设计与样本
- 回顾性队列研究,使用台湾全民健康保险研究数据库,分析2016年1月至2018年12月期间48,082例髋部骨折患者。
主要发现
- 队列中443例(0.9%)发生假体周围骨折,2285例(4.8%)发生对侧第二次髋部骨折。
- 60-69岁患者假体周围骨折风险较高。
- 抗骨质疏松药物使用与假体周围骨折风险降低显著相关(HR 0.50;95%CI 0.39-0.65),与对侧第二次髋部骨折风险降低显著相关(HR 0.85;95%CI 0.77-0.93)。
- 假体周围骨折组与对侧第二次髋部骨折组5年死亡率相当(33.0% vs 30.0%),但假体周围骨折组严重骨质疏松性骨折更常见(7.5% vs 3.7%)。
关键数值与推荐
- 抗骨质疏松药物使用与假体周围骨折风险降低相关(HR 0.50;95%CI 0.39-0.65)。
- 抗骨质疏松药物使用与对侧第二次髋部骨折风险降低相关(HR 0.85;95%CI 0.77-0.93)。
- 60-69岁患者假体周围骨折风险较高。
- 假体周围骨折组5年死亡率为33.0%,对侧第二次髋部骨折组为30.0%。
- 假体周围骨折组严重骨质疏松性骨折发生率为7.5%,对侧第二次髋部骨折组为3.7%。
临床怎么用
- 原文结论指出,髋部骨折后启用抗骨质疏松药物似乎可降低假体周围骨折和对侧第二次髋部骨折的风险,支持其作为关键预防策略的作用。
- 原文结论指出,需要进一步研究以优化治疗方案。
局限性
- 原文结论指出需要进一步研究以优化治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: People with a hip fracture are prone to break the bone around the metal repair, causing severe health issues. This study found that initiating anti-osteoporotic medication soon after the first fracture halves that risk, highlighting the benefit of early osteoporosis treatment. BACKGROUND: Hip fractures pose significant clinical challenges, often leading to prolonged hospitalization, reduced quality of life, and increased risk of subsequent fractures. Periprosthetic fractures (PPFs), which occur near hip fixation devices, are particularly concerning due to their high morbidity and mortality. This study evaluates the incidence, risk factors, and outcomes of PPFs and examines whether initiating anti-osteoporotic medication (AOM) after hip fracture reduces PPF risk. METHODS: We conducted a retrospective cohort study using Taiwan's National Health Insurance Research Database, analyzing 48,082 patients with hip fractures from January 2016 to December 2018. We assessed the incidence, risk factors, and prognosis of PPFs, including mortality and subsequent major osteoporotic fractures (SMOFs), and compared these outcomes to those with contralateral second hip fractures (2HFs). The effect of AOM initiation post-hip fracture was also evaluated. RESULTS: Among the cohort, 443 patients (0.9%) developed PPFs, and 2285 (4.8%) experienced 2HFs. Patients aged 60-69 had a higher PPF risk. AOM use was significantly associated with reduced risk of both PPFs (HR 0.50; 95% CI, 0.39-0.65) and 2HFs (HR 0.85; 95% CI, 0.77-0.93). Five-year mortality was comparable between PPF and 2HF groups (33.0% vs. 30.0%), but SMOFs were more frequent in PPF cases (7.5% vs. 3.7%). CONCLUSIONS: PPFs are a serious complication following hip fracture. Post-fracture AOM initiation appears to lower the risk of PPFs and 2HFs, supporting its role as a key preventive strategy. Further research is needed to optimize treatment protocols.
引用
- Lo SW, Yen HK, Huang CC, et al. Incidence, risk factors, prognosis of periprosthetic fractures post hip fracture: unveiling protective role of anti-osteoporotic medication. Osteoporos Int. 2025. PMID: 40921866. doi:10.1007/s00198-025-07670-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。